abstract: The influence of dietary fiber on determinants of @entity2 is controversial. The objective of this study was to determine the effects of NUTRIOSE supplementation on insulin resistance and the determinants of @entity2 in overweight @entity0 . In this double-blind, randomized, placebo-controlled study, we supplemented the diets of overweight Chinese @entity0 with 250  mL of fruit juice that contained NUTRIOSE (Test group: n = 60, age = 30.4     4.3  years, body mass index (BMI) = 24.5     0.2  kg  m-2) or a maltodextrin placebo ( CONTROL GROUP: n = 60, age = 31.6     4.1  years, BMI = 24.5     0.3  kg  m-2) at a dosage of 17 g twice daily for 12  weeks. Daily caloric intake, body composition, blood chemistry, and blood pressure were evaluated every 4  weeks during the trial. Test subjects consumed fewer calories per day and had greater reductions in body weight, BMI, body fat percentage, and waist circumference than Control subjects. All markers of @entity4 metabolism improved in the Test group, with increases in adiponectin and reductions in @entity4 , insulin, homeostasis model assessment-estimated insulin resistance, glycosylated hemoglobin, and glycated albumin (all p  < 0.01). Similarly, all lipid measures improved with increases in high-density lipoprotein @entity1 and reductions in total @entity1 , low-density lipoprotein @entity1 , very low-density lipoprotein @entity1 , and @entity5 (all p  < 0.01). No changes were observed in systolic blood pressure between groups. Most components of @entity4 metabolism and the lipid profile were significantly better in the Test than in the Control subjects. No adverse events or @entity3 were reported in either group. Supplementation with NUTRIOSE for 12  weeks is well tolerated, lowers insulin resistance, and improves determinants of @entity2 in overweight @entity0 .

title: NUTRIOSE dietary fiber supplementation improves insulin resistance and determinants of XXXX in overweight @entity0 : a double-blind, randomized, placebo-controlled study.

answer: @entity2


abstract: The influence of dietary fiber on determinants of @entity2 is controversial. The objective of this study was to determine the effects of NUTRIOSE supplementation on insulin resistance and the determinants of @entity2 in overweight @entity0 . In this double-blind, randomized, placebo-controlled study, we supplemented the diets of overweight Chinese @entity0 with 250  mL of fruit juice that contained NUTRIOSE (Test group: n = 60, age = 30.4     4.3  years, body mass index (BMI) = 24.5     0.2  kg  m-2) or a maltodextrin placebo ( CONTROL GROUP: n = 60, age = 31.6     4.1  years, BMI = 24.5     0.3  kg  m-2) at a dosage of 17 g twice daily for 12  weeks. Daily caloric intake, body composition, blood chemistry, and blood pressure were evaluated every 4  weeks during the trial. Test subjects consumed fewer calories per day and had greater reductions in body weight, BMI, body fat percentage, and waist circumference than Control subjects. All markers of @entity4 metabolism improved in the Test group, with increases in adiponectin and reductions in @entity4 , insulin, homeostasis model assessment-estimated insulin resistance, glycosylated hemoglobin, and glycated albumin (all p  < 0.01). Similarly, all lipid measures improved with increases in high-density lipoprotein @entity1 and reductions in total @entity1 , low-density lipoprotein @entity1 , very low-density lipoprotein @entity1 , and @entity5 (all p  < 0.01). No changes were observed in systolic blood pressure between groups. Most components of @entity4 metabolism and the lipid profile were significantly better in the Test than in the Control subjects. No adverse events or @entity3 were reported in either group. Supplementation with NUTRIOSE for 12  weeks is well tolerated, lowers insulin resistance, and improves determinants of @entity2 in overweight @entity0 .

title: NUTRIOSE dietary fiber supplementation improves insulin resistance and determinants of @entity2 in overweight XXXX : a double-blind, randomized, placebo-controlled study.

answer: @entity0


abstract: BACKGROUND: @entity2 during @entity3 are a known complication. The purpose of this study is to evaluate if significant changes in somatosensory evoked potentials and electroencephalography increase @entity2 during @entity3 . PROCEDURES: This is an observational retrospective case-control study analyzed with data collected from @entity0 who underwent @entity3 at the University of Pittsburgh Medical Center. Five hundred and eighty-seven @entity0 were included in the final analysis. Due to the small number of @entity2 and the comparatively large number of potential covariates, we used a regression analysis with Bayesian shrinkage. FINDINGS: Analysis was performed on 587 @entity0 , of which a total of 11 (1.8%) cases of @entity2 were recorded. The marginal mandibular branch of the facial nerve was injured in nine (81%) @entity0 and hypoglossal nerve was injured in two (19%) @entity0 . Of the 11 @entity0 , 9 cases resolved by the time of discharge, the 2 cases that persisted both were @entity4 . Multivariate analysis using Bayesian shrinkage showed that after adjusting for all risk factors only IOM changes increased the risk of @entity2 (OR 38.47, 95% CI 7.73, 191.42). CONCLUSIONS: @entity1 is 38 times more likely in @entity0 who experienced a change in IOM during @entity3 shunt. Future studies examining the effect of stretch and the degree of retraction on the CN might be more helpful in reducing @entity2 .

title: Risk factors for XXXX during carotid endarterectomy: A retrospective study.

answer: @entity2


abstract: BACKGROUND: Pneumococcal conjugate vaccine ( @entity1 ) induces protective anticapsular IgG, which mediates disease immunity. IgG persistence may influence long-term protection. METHODS: An observational, prospective, longitudinal study of nasopharyngeal carriage among American Indian households from 2006 to 2008 evaluated long-term immunogenicity of 7-valent @entity1 (PCV7). @entity0 unimmunized with @entity1 were age-matched to those PCV7 immunized at least 4 years prior (ratio 1:3 or 1:4). Blood collected at the final study visit was analyzed for PCV7 serotype IgG (enzyme-linked immunosorbent assay) and for functional activity (multiplex-opsonophagocytic assay) for serotypes 4, 6B, 14 and 23F. Geometric mean concentrations (GMCs), titers (GMTs) and the odds of serotype-specific IgG >= 0.35  g/mL were compared according to immunization status using a matched regression approach. RESULTS: Eight unimmunized and 28 immunized @entity0 age-matched at the time of serum collection (mean age: 7.9 years) were included. Serotype-specific GMCs, GMTs and proportions above the correlate of protection did not differ between the groups except for serotypes 14 and 23F. Serotype 14 GMCs (immunized 0.7 vs. unimmunized 0.2; P = 0.02) and serotype 23F GMTs (immunized 388.3 vs. unimmunized 47.8; P = 0.03) were significantly higher among immunized children. IgG concentrations and functional titers among immunized @entity0 were strongly correlated for serotypes 4 (r = 0.78; P  <= 0.001) and 14 (r = 0.52; P  <= 0.01). CONCLUSIONS: @entity1 serotype-specific IgG concentrations 4 years following @entity1 vaccination do not persist above natural levels for most serotypes. Exposure to pneumococcus may be critical in maintaining persistent serotype-specific IgG; the elimination of circulating vaccine type pneumococci by @entity1 may have effects on long-term immunity.

title: Persistence of IgG antibody following routine XXXX immunization with the 7-valent pneumococcal conjugate vaccine.

answer: @entity0


abstract: 1. The lipids and @entity4 of the lipids of testes of @entity0 aged 4 weeks to 6 months were separated and analysed. 2. A decrease in concentration of @entity2 was noted, but there was no significant change in the concentration of phospholipids, plasmalogen or @entity1 during this time. 3. There were no significant differences in the total lipid concentration of @entity8 , @entity5 , @entity7 , @entity3 and @entity12 between the various age groups. 4. A decrease in the concentration of @entity6 in the phosphatide and @entity2 fractions and an increase in the concentration of @entity10 (characterized as the @entity9 ,7,10,13,16-isomer) in @entity11 but not in @entity2 were observed during the maturation period. 5. Histological studies indicated that the lipid changes occurred at the same time as the appearance and maturation of the spermatids.

title: Changes in lipid composition of the maturing XXXX testis.

answer: @entity0


abstract: INTRODUCTION: @entity3 ( @entity3 ) is now a relatively uncommon disease in high income countries. As such, its diagnosis may be missed or delayed resulting in death before or shortly after the introduction of treatment. Whether early @entity1 is associated with increased @entity3 transmission is unknown. To determine the transmission risk attributable to early @entity1 we undertook a case-control study. METHODS: All adults who were: (1) diagnosed with culture-positive @entity5 in the Province of Alberta, Canada between 1996 and 2012, and (2) died a @entity1 before or within the first 60 days of treatment, were identified. For each of these "cases" two sets of "controls" were randomly selected from among culture-positive @entity5 cases that survived beyond 60 days of treatment. "Controls" were matched by age, sex, population group, +/- smear status. Secondary cases of "cases" and "controls" were identified using conventional and molecular epidemiologic tools and compared. In addition, new @entity2 were identified and compared in contacts of "cases" that died before treatment and contacts of their smear-matched "controls". Conditional logistic regression was used to find associations in both univariate and multivariate analysis. RESULTS: "Cases" were as, but not more, likely than "controls" to transmit. This was so whether transmission was measured in terms of the number of "cases" and smear-unmatched or -matched "controls" that had a secondary case, the number of secondary cases that they had or the number of new @entity2 found in contacts of "cases" that died before treatment and their smear-matched "controls". CONCLUSION: In a low @entity3 incidence/low @entity4 prevalence country, @entity5 @entity0 that die a @entity1 before or in the initial phase of treatment and @entity5 @entity0 that survive beyond the initial phase of treatment are equally likely to transmit.

title: Is Early XXXX Death Associated with Increased @entity3 Transmission?

answer: @entity3


abstract: INTRODUCTION: @entity3 ( @entity3 ) is now a relatively uncommon disease in high income countries. As such, its diagnosis may be missed or delayed resulting in death before or shortly after the introduction of treatment. Whether early @entity1 is associated with increased @entity3 transmission is unknown. To determine the transmission risk attributable to early @entity1 we undertook a case-control study. METHODS: All adults who were: (1) diagnosed with culture-positive @entity5 in the Province of Alberta, Canada between 1996 and 2012, and (2) died a @entity1 before or within the first 60 days of treatment, were identified. For each of these "cases" two sets of "controls" were randomly selected from among culture-positive @entity5 cases that survived beyond 60 days of treatment. "Controls" were matched by age, sex, population group, +/- smear status. Secondary cases of "cases" and "controls" were identified using conventional and molecular epidemiologic tools and compared. In addition, new @entity2 were identified and compared in contacts of "cases" that died before treatment and contacts of their smear-matched "controls". Conditional logistic regression was used to find associations in both univariate and multivariate analysis. RESULTS: "Cases" were as, but not more, likely than "controls" to transmit. This was so whether transmission was measured in terms of the number of "cases" and smear-unmatched or -matched "controls" that had a secondary case, the number of secondary cases that they had or the number of new @entity2 found in contacts of "cases" that died before treatment and their smear-matched "controls". CONCLUSION: In a low @entity3 incidence/low @entity4 prevalence country, @entity5 @entity0 that die a @entity1 before or in the initial phase of treatment and @entity5 @entity0 that survive beyond the initial phase of treatment are equally likely to transmit.

title: Is Early @entity3 Death Associated with Increased XXXX Transmission?

answer: @entity3


abstract: During estrous cycle as well as during pregnancy and after treatment with @entity0 and/or @entity2 uterine mucus secretory responses were studied as amount of @entity3 released from everted @entity1 uteri after transmural nerve stimulation of @entity4 administration. In estrous cycle both stimuli increased secretion by about 20% except for the late diestrus phase, when no secretory responses were seen. In pregnancy a secretory response was noted at implantation time. From mid pregnancy and onwards secretory responses of increasing magnitude were obtained. Secretory responses persisted post partum. Evidence of an adrenergic inhibitory influence on the neurogenic cholinergic responses during metestrus was noted. Both stimuli increased @entity3 release by about 50% above resting level in uteri from animals receiving combined hormone treatment. In uteri of animals receiving @entity0 only the increase was about 20%. No definite secretory response was obtained in uteri from animals receiving @entity2 only. It is suggested that both hormones are necessary for full cholinergic secretory response to nerve stimulation or muscarinic drugs. It is concluded that muscarinic stimulation of the endometrium results in mucus secretion during all crucial events during the reproductive cycle. Furthermore a cholinergic secretory innervation seems to be present at all these times.

title: Endometrial cholinergic secretory responses during estrous cycle, pregnancy and after XXXX and/or @entity2 treatment of the @entity1 .

answer: @entity0


abstract: During estrous cycle as well as during pregnancy and after treatment with @entity0 and/or @entity2 uterine mucus secretory responses were studied as amount of @entity3 released from everted @entity1 uteri after transmural nerve stimulation of @entity4 administration. In estrous cycle both stimuli increased secretion by about 20% except for the late diestrus phase, when no secretory responses were seen. In pregnancy a secretory response was noted at implantation time. From mid pregnancy and onwards secretory responses of increasing magnitude were obtained. Secretory responses persisted post partum. Evidence of an adrenergic inhibitory influence on the neurogenic cholinergic responses during metestrus was noted. Both stimuli increased @entity3 release by about 50% above resting level in uteri from animals receiving combined hormone treatment. In uteri of animals receiving @entity0 only the increase was about 20%. No definite secretory response was obtained in uteri from animals receiving @entity2 only. It is suggested that both hormones are necessary for full cholinergic secretory response to nerve stimulation or muscarinic drugs. It is concluded that muscarinic stimulation of the endometrium results in mucus secretion during all crucial events during the reproductive cycle. Furthermore a cholinergic secretory innervation seems to be present at all these times.

title: Endometrial cholinergic secretory responses during estrous cycle, pregnancy and after @entity0 and/or @entity2 treatment of the XXXX .

answer: @entity1


abstract: During estrous cycle as well as during pregnancy and after treatment with @entity0 and/or @entity2 uterine mucus secretory responses were studied as amount of @entity3 released from everted @entity1 uteri after transmural nerve stimulation of @entity4 administration. In estrous cycle both stimuli increased secretion by about 20% except for the late diestrus phase, when no secretory responses were seen. In pregnancy a secretory response was noted at implantation time. From mid pregnancy and onwards secretory responses of increasing magnitude were obtained. Secretory responses persisted post partum. Evidence of an adrenergic inhibitory influence on the neurogenic cholinergic responses during metestrus was noted. Both stimuli increased @entity3 release by about 50% above resting level in uteri from animals receiving combined hormone treatment. In uteri of animals receiving @entity0 only the increase was about 20%. No definite secretory response was obtained in uteri from animals receiving @entity2 only. It is suggested that both hormones are necessary for full cholinergic secretory response to nerve stimulation or muscarinic drugs. It is concluded that muscarinic stimulation of the endometrium results in mucus secretion during all crucial events during the reproductive cycle. Furthermore a cholinergic secretory innervation seems to be present at all these times.

title: Endometrial cholinergic secretory responses during estrous cycle, pregnancy and after @entity0 and/or XXXX treatment of the @entity1 .

answer: @entity2


abstract: In order to obtain some information about the state of hydration and possible haematological changes in @entity0 with delirium @entity5 (grade 3) and related clinical states (grade 2) various clinico-chemical variables were measured at the time of admission and repeatedly until clinical recovery from the @entity3 state. In grade 3 @entity0 plasma protein concentration, blood haemoglobin concentration, blood haematocrit and erythrocyte count decreased between admission and recovery probably reflecting a slight haemodilution. The changes were all within the normal range for the variables and there was thus no indication of hypo- or hypervolemia. Delirium @entity5 @entity0 without concomitant somatic diseases should not be routinely treated with intravenous fluid therapy. In grade 2 @entity0 no statistically significant changes occurred in the above mentioned variables. In the grade 3 @entity0 there was a dramatic (100%) increase in plasma @entity1 concentration between admission and the subsequent morning and this was probably related to the elimination of @entity4 from the body. In grade 2 @entity0 , where the initial blood @entity2 concentration was lower than in grade 3 @entity0 , no change in plasma @entity1 concentration occurred. A statistically significant increase in reticulocyte count between admission and recovery in both grade 3 and grade 2 @entity0 probably reflected the recovery of haemopoietic tissue from the insult of the preceding @entity4 intoxication. The same may be true for the prevailing anisocytosis, whereas the trend towards leucocytosis may be due to unspecific stress during the @entity4 withdrawal reaction. The rapid changes in some of the clinico-chemical variables stress the importance of initiating investigational procedures immediately at the hour of admission.

title: Haematological changes and state of hydration during delirium XXXX and related clinical states.

answer: @entity5


abstract: PURPOSE: Coronary artery bypass graft (CABG) surgery @entity0 participating in cardiac rehabilitation (CR) experience improvements in aerobic fitness, but there has been little study of outcomes for @entity2 ( @entity2 ) surgical @entity0 . The primary aims of this study were to evaluate baseline peak aerobic capacity for @entity2 @entity0 participating in CR and to compare outcomes between @entity2 and CABG @entity0 . METHODS: Five hundred seventy-six consecutive @entity0 who underwent @entity2 surgery (n = 125), @entity2 plus CABG surgery (n = 57), or CABG surgery (n = 394), all with classic sternotomy and enrolled in CR, were prospectively studied. Changes in outcomes were assessed for individuals who completed CR (n = 313). RESULTS: @entity2 @entity0 were significantly older and had a greater percentage of females than the CABG-only group. Combining @entity2 and @entity2 + CABG groups, @entity2 included 134 mitral, 39 aortic, and 8 combined abnormalities (mitral and aortic). For the entire cohort, the mean number of CR exercise sessions attended was 23.6    11.7. Peak @entity1 uptake ((Equation is included in full-text article.)) increased 19.5% from 17.4    4.4 to 20.8    5.5 mLO2  kg  min (P < .0001). Improvement in peak (Equation is included in full-text article.)with CR exercise training was similar between the 3 groups of @entity0 . Within the group of @entity0 who had @entity2 surgery, percentage change in peak (Equation is included in full-text article.)was not significantly different between the 3 types of @entity2 (ie, mitral [19.2%], aortic [24.4%], and mitral + aortic [21.9%]). CONCLUSIONS: @entity2 surgery @entity0 achieve similar improvement in aerobic fitness from participating in CR exercise training as individuals who had CABG. The observed improvements in aerobic fitness are similar, regardless of the type of @entity2 or whether CABG was performed concurrently.

title: Cardiac Rehabilitation After Heart Valve Surgery: COMPARISON WITH CORONARY ARTERY BYPASS GRAFT XXXX .

answer: @entity0


abstract: BACKGROUND _ AIMS: @entity1 ( @entity1 ) usually recurs after intestinal resection; postoperative endoscopic monitoring and tailored treatment can reduce the chance of recurrence. We investigated whether monitoring levels of fecal calprotectin (FC) can substitute for endoscopic analysis of the mucosa. METHODS: We analyzed data collected from 135 @entity0 in a prospective, randomized, controlled trial, performed at 17 hospitals in Australia and 1 hospital in New Zealand, that assessed the ability of endoscopic evaluations and step-up treatment to prevent @entity1 recurrence after surgery. Levels of FC, serum levels of @entity2 ( @entity2 ), and @entity1 activity index (CDAI) scores were measured before surgery and then at 6, 12, and 18 months after resection of all macroscopic @entity1 . Ileocolonoscopies were performed at 6 months after surgery in 90 @entity0 and at 18 months after surgery in all @entity0 . RESULTS: Levels of FC were measured in 319 samples from 135 @entity0 . The median FC level decreased from 1347  g/g before surgery to 166  g/g at 6 months after surgery, but was higher in @entity0 with disease recurrence (based on endoscopic analysis; Rutgeerts score, >= i2) than in @entity0 in remission (275 vs 72  g/g, respectively; P < .001). Combined 6- and 18-month levels of FC correlated with the presence (r  = 0.42; P < .001) and severity (r  = 0.44; P < .001) of @entity1 recurrence, but the @entity2 level and CDAI score did not. Levels of FC greater than 100  g/g indicated endoscopic recurrence with 89% sensitivity and 58% specificity, and a negative predictive value (NPV) of 91%; this means that colonoscopy could have been avoided in 47% of @entity0 . Six months after surgery, FC levels less than 51  g/g in @entity0 in endoscopic remission predicted maintenance of remission (NPV, 79%). In @entity0 with endoscopic recurrence at 6 months who stepped-up treatment, FC levels decreased from 324  g/g at 6 months to 180  g/g at 12 months and 109  g/g at 18 months. CONCLUSIONS: In this analysis of data from a prospective clinical trial, FC measurement has sufficient sensitivity and NPV values to monitor for @entity1 recurrence after intestinal resection. Its predictive value might be used to identify @entity0 most likely to relapse. After treatment for recurrence, the FC level can be used to monitor response to treatment. It predicts which @entity0 will have disease recurrence with greater accuracy than @entity2 level or CDAI score.

title: Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of XXXX After Surgery.

answer: @entity1


abstract: BACKGROUND: Currently, researches about @entity8 ( @entity8 ) are various, but long-term reviews assessing relevant complications after @entity8 with considerable amount of case series are rare. STUDY DESIGN: We retrospectively reviewed a large series of 529 @entity0 undergoing @entity8 to assess the long-term postoperative recovery, including @entity1 , retained symptoms, and quality of life. Finally, we assessed its associated risk factors related to @entity8 @entity0 ' recovery in the long term. RESULTS: During a mean follow-up period of 36.8      8.8  months after @entity8 , 402 (76.0  %) @entity0 underwent complete resolution. Frequent @entity3 (12.1  %) and recurrent omphalitis (5.9  %) were most commonly seen among other complications and retained symptoms within overall the @entity0 . We identified 1 (0.3  %) incision @entity4 and 1 (0.3  %) intra-abdominal abscess among overall the @entity0 , while 3 (0.8  %) common bile duct stones and 1 (0.3  %) @entity5 among the @entity0 with symptomatic @entity7 during long-term review period. No significant differences were identified between @entity0 with symptomatic @entity7 and @entity6 when considering other incidences (all p  >  0.05). @entity0 undergoing @entity8 with older age (p  =  0.023) or female gender (p  =  0.020) contributed to complete resolution. CONCLUSIONS: @entity8 via traditional devices is feasible and safe with acceptable postoperative incidence rate in the long run. @entity0 with older age or female gender, who have no severe @entity2 , tend to benefit more from the surgical intervention.

title: Transumbilical XXXX : long-term review from a single center.

answer: @entity8


abstract: AIM: To assess the safety and efficacy of cold loop myomectomy applied to @entity1 to perform "one-step" myomectomy of @entity3 with intramural involvement. METHODS: Seventy-two @entity0 with at least one symptomatic G1 or G2 @entity3 (Wamsteker's classification) underwent cold loop myomectomy from January 2011 to January 2013. All surgical procedures were performed using a 26Fr resectoscope and bipolar energy source. At one month after the procedure, all @entity0 underwent an office hysteroscopy check-up. A subgroup of seven @entity2 @entity0 underwent an office hysteroscopy every two-weeks to evaluate recovery time of the myometrial fovea. RESULTS: Resectoscopic myomectomies were successfully performed in one surgical step in 70 out of 72 @entity0 without any significant complications. Overall, the mean diameter of resected @entity3 was 32.2        9 mm. Median operative time was 34.2        24.1 min. Median fluid deficit was 761.22        480.34 ml. The fovea was almost completely restored (>80%) six weeks after surgery in six of the seven @entity2 @entity0 who underwent repeated follow-up office hysteroscopies every two weeks. CONCLUSIONS: Data from the present study show that the use of cold loops applied to @entity1 represent an effective, safe technique for "one-step" myomectomy of @entity3 , allowing rapid recovery of the myometrial fovea.

title: Cold loops applied to XXXX : A safe "one-step" myomectomy for treatment of @entity3 with intramural development.

answer: @entity1


abstract: AIM: To assess the safety and efficacy of cold loop myomectomy applied to @entity1 to perform "one-step" myomectomy of @entity3 with intramural involvement. METHODS: Seventy-two @entity0 with at least one symptomatic G1 or G2 @entity3 (Wamsteker's classification) underwent cold loop myomectomy from January 2011 to January 2013. All surgical procedures were performed using a 26Fr resectoscope and bipolar energy source. At one month after the procedure, all @entity0 underwent an office hysteroscopy check-up. A subgroup of seven @entity2 @entity0 underwent an office hysteroscopy every two-weeks to evaluate recovery time of the myometrial fovea. RESULTS: Resectoscopic myomectomies were successfully performed in one surgical step in 70 out of 72 @entity0 without any significant complications. Overall, the mean diameter of resected @entity3 was 32.2        9 mm. Median operative time was 34.2        24.1 min. Median fluid deficit was 761.22        480.34 ml. The fovea was almost completely restored (>80%) six weeks after surgery in six of the seven @entity2 @entity0 who underwent repeated follow-up office hysteroscopies every two weeks. CONCLUSIONS: Data from the present study show that the use of cold loops applied to @entity1 represent an effective, safe technique for "one-step" myomectomy of @entity3 , allowing rapid recovery of the myometrial fovea.

title: Cold loops applied to @entity1 : A safe "one-step" myomectomy for treatment of XXXX with intramural development.

answer: @entity3


abstract: PURPOSE: Ipilimumab is a first-in-class immune checkpoint inhibitor approved for treatment of @entity5 but not studied in @entity0 until this phase I protocol. EXPERIMENTAL DESIGN: This study examined safety, pharmacokinetics, and immunogenicity, and immune correlates of ipilimumab administered to subjects <= 21 years old with recurrent or progressive @entity1 . Dose escalation cohorts received 1, 3, 5, or 10 mg/m(2) intravenously every 3 weeks in a 3 + 3 design. Response was assessed after 6 weeks and 12 weeks, and then every 3 months. Treatment was continued until disease progression or unacceptable @entity3 . RESULTS: Thirty-three @entity0 received 72 doses of ipilimumab. @entity0 enrolled had @entity5 (n = 12), @entity4 (n = 17), or other refractory @entity1 (n = 4). Immune-related adverse events included @entity7 , @entity2 , @entity9 , @entity10 , and transaminitis with dose-limiting @entity3 observed at 5 and 10 mg/kg dose levels. Pharmacokinetics revealed a half-life of 8 to 15 days. At day 21, subjects had increased levels of cycling T cells, but no change in regulatory T-cell populations. Six subjects had confirmed stable disease for 4 to 10 cycles ( @entity5 , @entity6 , @entity11 , and @entity8 ). CONCLUSIONS: Ipilimumab was safely administered to pediatric @entity0 using management algorithms for immune-related @entity3 . The spectrum of immune-related adverse events is similar to those described in adults; however, many of the pediatric @entity3 were evident after a single dose. Although no objective @entity1 regressions were observed with ipilimumab as a single agent, subjects with immune-related @entity3 had an increased overall survival compared with those who showed no evidence of breaking tolerance.

title: Phase I Clinical Trial of Ipilimumab in Pediatric @entity0 with XXXX .

answer: @entity1


abstract: PURPOSE: Ipilimumab is a first-in-class immune checkpoint inhibitor approved for treatment of @entity5 but not studied in @entity0 until this phase I protocol. EXPERIMENTAL DESIGN: This study examined safety, pharmacokinetics, and immunogenicity, and immune correlates of ipilimumab administered to subjects <= 21 years old with recurrent or progressive @entity1 . Dose escalation cohorts received 1, 3, 5, or 10 mg/m(2) intravenously every 3 weeks in a 3 + 3 design. Response was assessed after 6 weeks and 12 weeks, and then every 3 months. Treatment was continued until disease progression or unacceptable @entity3 . RESULTS: Thirty-three @entity0 received 72 doses of ipilimumab. @entity0 enrolled had @entity5 (n = 12), @entity4 (n = 17), or other refractory @entity1 (n = 4). Immune-related adverse events included @entity7 , @entity2 , @entity9 , @entity10 , and transaminitis with dose-limiting @entity3 observed at 5 and 10 mg/kg dose levels. Pharmacokinetics revealed a half-life of 8 to 15 days. At day 21, subjects had increased levels of cycling T cells, but no change in regulatory T-cell populations. Six subjects had confirmed stable disease for 4 to 10 cycles ( @entity5 , @entity6 , @entity11 , and @entity8 ). CONCLUSIONS: Ipilimumab was safely administered to pediatric @entity0 using management algorithms for immune-related @entity3 . The spectrum of immune-related adverse events is similar to those described in adults; however, many of the pediatric @entity3 were evident after a single dose. Although no objective @entity1 regressions were observed with ipilimumab as a single agent, subjects with immune-related @entity3 had an increased overall survival compared with those who showed no evidence of breaking tolerance.

title: Phase I Clinical Trial of Ipilimumab in Pediatric XXXX with @entity1 .

answer: @entity0


abstract: BACKGROUND: Laser lithotripsy of @entity8 in tetraplegic subjects with long-term urinary catheters is fraught with complications because of @entity6 , @entity3 , fragile urothelium, @entity6 , and @entity10 . Severe haematuria should be anticipated; failure to institute measures to minimise @entity5 and prevent clot retention can be catastrophic. We present an illustrative case. CASE PRESENTATION: A tetraplegic @entity0 underwent laser lithotripsy of vesical stone under general anaesthesia. During lithotripsy, severe @entity6 and consequent rise in blood pressure occurred. Bleeding continued post-operatively resulting in clot retention. CT revealed clots within distended but intact bladder. Clots were sucked out and continuous @entity6 was commenced. Bleeding persisted; @entity0 developed repeated clot retention. Cystoscopy was performed to remove clots. @entity0 developed @entity7 . @entity6 was suspected; bed-side ultrasound scan revealed @entity4 with mild peritoneal effusion; under-filled bladder containing small clot. @entity0 developed @entity7 and ileus. Two days later, CT with oral positive contrast revealed intra-peritoneal haematoma at the dome of bladder with perforation at the site of haematoma. Free fluid was noted within the peritoneal cavity. This @entity0 was managed by gastric drainage and intravenous fluids. @entity0 's condition improved gradually with urethral catheter drainage. Follow-up CT revealed resolution of @entity6 , perivesical haematoma, and intra-peritoneal free fluid. CONCLUSION: If @entity5 occurs, @entity6 should be commenced immediately after surgery to prevent clot retention. When @entity6 is suspected, CT of abdomen should be done instead of ultrasound scan, which may not reveal @entity6 . It is debatable whether laparotomy and repair of @entity6 is preferable to nonoperative management in tetraplegics. Anti-muscarinic drugs should be prescribed prior to lithotripsy to control @entity6 ; @entity1 and @entity9 should be omitted. If significant @entity5 occurs during lithotripsy, procedure should be stopped and rescheduled. Percutaneous cystolithotripsy using a wide channel could be quicker to clear stones, as larger fragments could be retrieved; lesser stimulant for triggering @entity10 , as it avoids urethral manipulation. But in @entity0 with small, @entity6 , and protuberant abdomen, percutaneous access to urinary bladder may be difficult and can result in @entity2 .

title: Complications and salvage options after laser lithotripsy for a XXXX in a tetraplegic @entity0 : a case report.

answer: @entity8


abstract: BACKGROUND: Laser lithotripsy of @entity8 in tetraplegic subjects with long-term urinary catheters is fraught with complications because of @entity6 , @entity3 , fragile urothelium, @entity6 , and @entity10 . Severe haematuria should be anticipated; failure to institute measures to minimise @entity5 and prevent clot retention can be catastrophic. We present an illustrative case. CASE PRESENTATION: A tetraplegic @entity0 underwent laser lithotripsy of vesical stone under general anaesthesia. During lithotripsy, severe @entity6 and consequent rise in blood pressure occurred. Bleeding continued post-operatively resulting in clot retention. CT revealed clots within distended but intact bladder. Clots were sucked out and continuous @entity6 was commenced. Bleeding persisted; @entity0 developed repeated clot retention. Cystoscopy was performed to remove clots. @entity0 developed @entity7 . @entity6 was suspected; bed-side ultrasound scan revealed @entity4 with mild peritoneal effusion; under-filled bladder containing small clot. @entity0 developed @entity7 and ileus. Two days later, CT with oral positive contrast revealed intra-peritoneal haematoma at the dome of bladder with perforation at the site of haematoma. Free fluid was noted within the peritoneal cavity. This @entity0 was managed by gastric drainage and intravenous fluids. @entity0 's condition improved gradually with urethral catheter drainage. Follow-up CT revealed resolution of @entity6 , perivesical haematoma, and intra-peritoneal free fluid. CONCLUSION: If @entity5 occurs, @entity6 should be commenced immediately after surgery to prevent clot retention. When @entity6 is suspected, CT of abdomen should be done instead of ultrasound scan, which may not reveal @entity6 . It is debatable whether laparotomy and repair of @entity6 is preferable to nonoperative management in tetraplegics. Anti-muscarinic drugs should be prescribed prior to lithotripsy to control @entity6 ; @entity1 and @entity9 should be omitted. If significant @entity5 occurs during lithotripsy, procedure should be stopped and rescheduled. Percutaneous cystolithotripsy using a wide channel could be quicker to clear stones, as larger fragments could be retrieved; lesser stimulant for triggering @entity10 , as it avoids urethral manipulation. But in @entity0 with small, @entity6 , and protuberant abdomen, percutaneous access to urinary bladder may be difficult and can result in @entity2 .

title: Complications and salvage options after laser lithotripsy for a @entity8 in a tetraplegic XXXX : a case report.

answer: @entity0


abstract: Standard coagulation tests have a low specificity and sensitivity for diagnosing disseminated @entity3 . The aim of this study was to determine whether whole blood thromboelastometry (TEM) detects lipopolysaccharide (LPS)-induced changes in coagulation. Blood samples from 10 @entity0 were drawn at baseline, before and at the end of LPS infusion and 2, 3, 4 and 5 h after the start of endotoxinemia. Simultaneous to TEM, standard coagulation tests and extended coagulation analysis including tissue plasminogen activator ( @entity5 ) and @entity4 ( @entity4 ) were performed. Endotoxinemia resulted in a significant acceleration of the nonactivated TEM (NATEM) clotting time 2 h after the end of LPS infusion; in contrast, the changes in international normalized ratio and activated partial thromboplastin time suggested delayed @entity1 . NATEM @entity2 ( @entity2 ) and fibrin-based thromboelastometry test (FIBTEM)- @entity2 decreased significantly from baseline until the last time point (from 64.6    7.8 and 35.1    12.8 mm to 52.8    4.6 and 21.4    11.8 mm, respectively; P = 0.01 for both parameters). A sharp, transient increase of @entity5 had no effect on maximum lysis in the NATEM test. @entity4 increased significantly 3 h after the start of LPS infusion, paralleled by a decrease in maximum lysis. In conclusion, TEM was superior to standard coagulation tests in reflecting initial activation of coagulation during endotoxinemia. TEM further suggested consumption of coagulation substrate; at the same time, inhibition of plasminogen activation was accompanied by improved clot stability. Further investigations are necessary to establish the clinical relevance of these findings.

title: Thromboelastometry (TEM) findings in disseminated @entity3 in a XXXX model of endotoxinemia.

answer: @entity0


abstract: Standard coagulation tests have a low specificity and sensitivity for diagnosing disseminated @entity3 . The aim of this study was to determine whether whole blood thromboelastometry (TEM) detects lipopolysaccharide (LPS)-induced changes in coagulation. Blood samples from 10 @entity0 were drawn at baseline, before and at the end of LPS infusion and 2, 3, 4 and 5 h after the start of endotoxinemia. Simultaneous to TEM, standard coagulation tests and extended coagulation analysis including tissue plasminogen activator ( @entity5 ) and @entity4 ( @entity4 ) were performed. Endotoxinemia resulted in a significant acceleration of the nonactivated TEM (NATEM) clotting time 2 h after the end of LPS infusion; in contrast, the changes in international normalized ratio and activated partial thromboplastin time suggested delayed @entity1 . NATEM @entity2 ( @entity2 ) and fibrin-based thromboelastometry test (FIBTEM)- @entity2 decreased significantly from baseline until the last time point (from 64.6    7.8 and 35.1    12.8 mm to 52.8    4.6 and 21.4    11.8 mm, respectively; P = 0.01 for both parameters). A sharp, transient increase of @entity5 had no effect on maximum lysis in the NATEM test. @entity4 increased significantly 3 h after the start of LPS infusion, paralleled by a decrease in maximum lysis. In conclusion, TEM was superior to standard coagulation tests in reflecting initial activation of coagulation during endotoxinemia. TEM further suggested consumption of coagulation substrate; at the same time, inhibition of plasminogen activation was accompanied by improved clot stability. Further investigations are necessary to establish the clinical relevance of these findings.

title: Thromboelastometry (TEM) findings in disseminated XXXX in a @entity0 model of endotoxinemia.

answer: @entity3


abstract: BACKGROUND: @entity0 seek @entity2 ( @entity2 ) treatments for a variety of @entity3 , e.g., @entity1 and @entity4 ( @entity4 ). No previous studies have reviewed the data available in medical records from Australian clinics. This study aims to identify the characteristics of @entity0 with @entity3 who visited a @entity2 teaching clinic at RMIT University in Melbourne, Australia. METHODS: Primary data from January 2010 to December 2011 were collected from @entity0 records in a @entity2 teaching clinic at RMIT University. @entity0 data, including demographics, primary complaint, clinical history, lifestyle, @entity2 treatment, and adverse events, were analyzed with descriptive statistics and the Chi square test using SPSS version 21.0. RESULTS: From 1677 clinical records we identified 261 @entity0 with @entity3 . The @entity0 made a total of 842 visits (mean: 3.2 visits/ @entity0 ; range: 1-34 visits) during the study period. The mean age of the @entity0 was 38.5      17.9  years, and the majority were female (65.5  %). The most common @entity3 were @entity4 (27.8  %), cough (20.8  %), @entity5 or @entity5 (18.6  %), sinus congestion (11.2  %), and @entity1 (7.6  %). Acupuncture was given at almost all visits (97.5  %) and was frequently combined with herbs (64.0  %). Fifteen adverse events were reported, but none were considered severe. CONCLUSION: In the @entity2 teaching clinic, respiratory conditions were a common presenting complaint of @entity0 , and were safely treated with a combination of acupuncture and herbs.

title: Management of XXXX in a @entity2 teaching clinic in Australia: review of clinical records.

answer: @entity3


abstract: BACKGROUND: @entity0 seek @entity2 ( @entity2 ) treatments for a variety of @entity3 , e.g., @entity1 and @entity4 ( @entity4 ). No previous studies have reviewed the data available in medical records from Australian clinics. This study aims to identify the characteristics of @entity0 with @entity3 who visited a @entity2 teaching clinic at RMIT University in Melbourne, Australia. METHODS: Primary data from January 2010 to December 2011 were collected from @entity0 records in a @entity2 teaching clinic at RMIT University. @entity0 data, including demographics, primary complaint, clinical history, lifestyle, @entity2 treatment, and adverse events, were analyzed with descriptive statistics and the Chi square test using SPSS version 21.0. RESULTS: From 1677 clinical records we identified 261 @entity0 with @entity3 . The @entity0 made a total of 842 visits (mean: 3.2 visits/ @entity0 ; range: 1-34 visits) during the study period. The mean age of the @entity0 was 38.5      17.9  years, and the majority were female (65.5  %). The most common @entity3 were @entity4 (27.8  %), cough (20.8  %), @entity5 or @entity5 (18.6  %), sinus congestion (11.2  %), and @entity1 (7.6  %). Acupuncture was given at almost all visits (97.5  %) and was frequently combined with herbs (64.0  %). Fifteen adverse events were reported, but none were considered severe. CONCLUSION: In the @entity2 teaching clinic, respiratory conditions were a common presenting complaint of @entity0 , and were safely treated with a combination of acupuncture and herbs.

title: Management of @entity3 in a XXXX teaching clinic in Australia: review of clinical records.

answer: @entity2


abstract: PURPOSE: Previous aortic valve replacement (AVR) is considered to be an independent risk factor for late acute @entity4 (AAAD). However, the predictors of late AAAD at the time of AVR have not been characterized. METHODS: A total of 285 @entity0 who underwent isolated AVR were followed for 7.6    8.1 years (mean    SD). These 285 @entity0 were divided into two groups. Group A consisted of 275 @entity0 who did not develop late aortic complications after AVR, and group B consisted of 10 @entity0 (3.5%) who developed late AAAD after AVR. RESULTS: The mean time interval between initial AVR and developing late AAAD was 6.1    5.2 years. The diameter of the ascending aorta at the time of AVR was significantly greater in group B than those of group A (47.7    4.6 vs. 35.6    6.3 mm; P < 0.001). Univariate analysis identified other predictors as well: @entity2 (P = 0.029), systemic @entity1 (P < 0.001), thinning or fragility of the aortic wall (P < 0.001), and male sex (P = 0.039). CONCLUSION: @entity2 combined with systemic @entity1 , male sex, and thinned or fragile aortic walls in @entity0 with ascending @entity3 (>= 45 mm diameter) at the time of AVR may be predisposing factors for postsurgical aortic complications. These @entity0 should be considered for concomitant replacement of the ascending aorta unless the @entity0 has a high operative risk or older age.

title: Risk factor analysis for acute XXXX after aortic valve replacement.

answer: @entity4


abstract: The effects of intravenously administered @entity7 on the cerebral cortical energy state and glycolytic metabolism were studied in @entity0 . In one series, @entity0 were divided into five groups according to EEG patterns, i.e., control, desynchronized, synchronized, @entity1 (1-min duration) and recovery groups. With @entity7 infusion (0.75 mg/min), there were no significant changes from the control group in the cerebral energy state except for a modest increase in @entity4 (PCr) in the @entity1 group and a small decrease in @entity2 in the non- @entity1 groups. The cerebral energy charge remained unchanged. Lactate and @entity5 significantly decreased in the non- @entity1 groups. In a second series, @entity0 were divided into five groups, i.e., control, @entity7 @entity1 groups (5-min duration, 1.5 mg/min) at @entity9 , normocapnia and @entity6 , and a @entity3 (1.2 mg/kg) @entity1 group. The metabolic changes during @entity7 @entity1 were essentially the same as those observed in the @entity1 group in the first series. However, the increase in PCr during @entity7 @entity1 was significant only in the hypocapnic and the normocapnic groups. @entity3 -induced @entity1 were accompanied by a significant decrease in high energy @entity8 . In summary, neither a non- @entity1 nor- @entity1 dose of @entity7 caused any reduction in the cerebral energy charge nor was there any evidence of increased anaerobic metabolism in the cerebral cortex during @entity7 -induced @entity1 .

title: Cerebral energy state and glycolytic metabolism during XXXX infusion in the @entity0 .

answer: @entity7


abstract: The effects of intravenously administered @entity7 on the cerebral cortical energy state and glycolytic metabolism were studied in @entity0 . In one series, @entity0 were divided into five groups according to EEG patterns, i.e., control, desynchronized, synchronized, @entity1 (1-min duration) and recovery groups. With @entity7 infusion (0.75 mg/min), there were no significant changes from the control group in the cerebral energy state except for a modest increase in @entity4 (PCr) in the @entity1 group and a small decrease in @entity2 in the non- @entity1 groups. The cerebral energy charge remained unchanged. Lactate and @entity5 significantly decreased in the non- @entity1 groups. In a second series, @entity0 were divided into five groups, i.e., control, @entity7 @entity1 groups (5-min duration, 1.5 mg/min) at @entity9 , normocapnia and @entity6 , and a @entity3 (1.2 mg/kg) @entity1 group. The metabolic changes during @entity7 @entity1 were essentially the same as those observed in the @entity1 group in the first series. However, the increase in PCr during @entity7 @entity1 was significant only in the hypocapnic and the normocapnic groups. @entity3 -induced @entity1 were accompanied by a significant decrease in high energy @entity8 . In summary, neither a non- @entity1 nor- @entity1 dose of @entity7 caused any reduction in the cerebral energy charge nor was there any evidence of increased anaerobic metabolism in the cerebral cortex during @entity7 -induced @entity1 .

title: Cerebral energy state and glycolytic metabolism during @entity7 infusion in the XXXX .

answer: @entity0


abstract: BACKGROUND AND STUDY AIMS: Current guidelines recommend using endoscopic ultrasound (EUS), @entity4 ( @entity4 ) testing and cytology to manage incidental @entity5 ( @entity5 ); however, studies suggest a strategy including integrated molecular pathology (IMP) of cyst fluid may further aid in predicting risk of @entity1 . Here, we evaluate several strategies for diagnosing and managing asymptomatic @entity5 using healthcare economic modeling. @entity0 AND METHODS: A third-party-payer perspective Markov decision model examined four management strategies in a hypothetical cohort of 1000 asymptomatic @entity0 incidentally found to have a 3cm solitary @entity3 . Strategy I used cross-sectional imaging, recommended surgery only if symptoms or risk factors emerged. Strategy II considered @entity0 for resection without initial EUS.Strategy III (EUS+ @entity4 +Cytology) referred only those with @entity2 ( @entity4 >192ng/mL) for resection. Strategy IV implemented IMP; a commercially available panel provided a "Benign," "Mucinous," or "Aggressive" classification based on the level of mutational change in cyst fluid. "Benign" and "Mucinous" @entity0 were followed with surveillance; "Aggressive" @entity0 were referred for resection. Quality-adjusted life-years (QALY), relative risk with 95%CI, Number Needed to Treat (NNT), and incremental cost-effectiveness ratios were calculated. RESULTS: Strategy IV provided the greatest increase in QALY at nearly identical cost to the cheapest approach, Strategy I. Relative risk of @entity1 compared to the current standard of care and nearest competing strategy, Strategy III, was 0.18 (95%CI 0.06-0.53) with an NNT of 56 (95%CI 34-120). CONCLUSIONS: Use of IMP was the most cost-effective strategy, supporting its routine clinical use.

title: Managing incidental XXXX with integrated molecular pathology is a cost-effective strategy.

answer: @entity5


abstract: OBJECTIVE: the study was aimed at assessment of the efficacy of percutaneous high frequency selective rhizotomy (PHFSR) after failure of conservative treatment of @entity3 ( @entity3 ) in @entity1 ( @entity1 ). MATERIAL AND METHODS: A retrospective analysis of 28 @entity0 with @entity3 associated with @entity1 who underwent percutaneous rhizotomy in the period from 2000 to 2014 was performed. All @entity0 were definitely diagnosed with @entity1 according to the McDonald criteria (version of 2001, 2005, and 2010). The @entity0 were divided by age, gender, and the trigeminal nerve branches involved in the process. The @entity0 ' condition was evaluated at different times after surgery. RESULTS: Good outcomes in the form of @entity2 syndrome regression were achieved in 100% of the @entity0 . A disease recurrence was observed in 6 (21%) @entity0 during a follow-up period of 3 months to 14 years. Dysesthesia complications occurred in 4 (14%) @entity0 . There were no deaths and severe complications. The percentage of minor complications was low. CONCLUSION: These data confirm that PHFSR is a safe, repeatable, and effective method of symptomatic neurosurgical treatment of @entity3 associated with @entity1 and may be recommended in the case of failure/intolerance of medication.

title: [Experience in the use of high-frequency selective percutaneous rhizotomy in XXXX associated with @entity1 ].

answer: @entity3


abstract: OBJECTIVE: the study was aimed at assessment of the efficacy of percutaneous high frequency selective rhizotomy (PHFSR) after failure of conservative treatment of @entity3 ( @entity3 ) in @entity1 ( @entity1 ). MATERIAL AND METHODS: A retrospective analysis of 28 @entity0 with @entity3 associated with @entity1 who underwent percutaneous rhizotomy in the period from 2000 to 2014 was performed. All @entity0 were definitely diagnosed with @entity1 according to the McDonald criteria (version of 2001, 2005, and 2010). The @entity0 were divided by age, gender, and the trigeminal nerve branches involved in the process. The @entity0 ' condition was evaluated at different times after surgery. RESULTS: Good outcomes in the form of @entity2 syndrome regression were achieved in 100% of the @entity0 . A disease recurrence was observed in 6 (21%) @entity0 during a follow-up period of 3 months to 14 years. Dysesthesia complications occurred in 4 (14%) @entity0 . There were no deaths and severe complications. The percentage of minor complications was low. CONCLUSION: These data confirm that PHFSR is a safe, repeatable, and effective method of symptomatic neurosurgical treatment of @entity3 associated with @entity1 and may be recommended in the case of failure/intolerance of medication.

title: [Experience in the use of high-frequency selective percutaneous rhizotomy in @entity3 associated with XXXX ].

answer: @entity1


abstract: BACKGROUND: @entity0 with @entity2 were reported to benefit from adding @entity5 -based concurrent chemotherapy to two-dimensional conventional radiotherapy. But this benefit becomes uncertain in the intensity-modulated radiotherapy (IMRT) era, owing to its significant advantage. METHODS: We enrolled 661 low risk (T1N1M0, T2N0-1M0 or T3N0M0, the 2010 UICC/AJCC staging system) @entity0 who underwent IMRT with or without concurrent chemotherapy. Particularly, @entity0 with IMRT alone or IMRT plus @entity5 -based concurrent chemotherapy were equally matched using propensity-score matching method. @entity6 ( @entity6 ), distant @entity1 -free survival (DMFS) and locoregional relapse-free survival (LRFS) were assessed with Kaplan-Meier method, log-rank test and Cox regression. RESULTS: Among 661 @entity0 , IMRT alone achieved parallel @entity6 (P = 0.379), DMFS (P = 0.169) and LRFS (P = 0.849) to IMRT plus concurrent chemotherapy. In the propensity-matched cohort of 482 @entity0 , similar survival were observed between both arms (4-years @entity6 97.4% vs 96.1%, P = 0.134; DMFS 96.5% vs 95.1%, P = 0.763; LRFS 93.8% vs 91.5%, P = 0.715). In multivariate analysis, @entity5 -based concurrent chemotherapy did not lower the risk of @entity4 , distant @entity1 or locoregional relapse. And this association remained unchanged in subgroups by age, sex, histology and stage. CONCLUSIONS: In this study, low risk @entity3 @entity0 who underwent IMRT could not benefit from @entity5 -based concurrent chemotherapy.

title: Propensity score matching analysis of XXXX -based concurrent chemotherapy in low risk @entity3 in the intensity-modulated radiotherapy era.

answer: @entity5


abstract: BACKGROUND: @entity0 with @entity2 were reported to benefit from adding @entity5 -based concurrent chemotherapy to two-dimensional conventional radiotherapy. But this benefit becomes uncertain in the intensity-modulated radiotherapy (IMRT) era, owing to its significant advantage. METHODS: We enrolled 661 low risk (T1N1M0, T2N0-1M0 or T3N0M0, the 2010 UICC/AJCC staging system) @entity0 who underwent IMRT with or without concurrent chemotherapy. Particularly, @entity0 with IMRT alone or IMRT plus @entity5 -based concurrent chemotherapy were equally matched using propensity-score matching method. @entity6 ( @entity6 ), distant @entity1 -free survival (DMFS) and locoregional relapse-free survival (LRFS) were assessed with Kaplan-Meier method, log-rank test and Cox regression. RESULTS: Among 661 @entity0 , IMRT alone achieved parallel @entity6 (P = 0.379), DMFS (P = 0.169) and LRFS (P = 0.849) to IMRT plus concurrent chemotherapy. In the propensity-matched cohort of 482 @entity0 , similar survival were observed between both arms (4-years @entity6 97.4% vs 96.1%, P = 0.134; DMFS 96.5% vs 95.1%, P = 0.763; LRFS 93.8% vs 91.5%, P = 0.715). In multivariate analysis, @entity5 -based concurrent chemotherapy did not lower the risk of @entity4 , distant @entity1 or locoregional relapse. And this association remained unchanged in subgroups by age, sex, histology and stage. CONCLUSIONS: In this study, low risk @entity3 @entity0 who underwent IMRT could not benefit from @entity5 -based concurrent chemotherapy.

title: Propensity score matching analysis of @entity5 -based concurrent chemotherapy in low risk XXXX in the intensity-modulated radiotherapy era.

answer: @entity3


abstract: In 1978 and 1979, eight sporadic cases of @entity2 were observed in the Berne and Ticino areas of Switzerland. In all cases the diagnosis was established serologically using indirect immunofluorescence. Seroconversion was observed in five @entity0 . In three cases initially high antibody titers decreased progressively. The clinical picture was characterized by acute onset with high fever, frequent chills, and dry cough. Occasional concomitant symptoms included @entity3 , @entity1 , @entity3 , @entity5 , hemoptysis, and @entity4 . Laboratory findings showed markedly increased BSR as well as slightly increased WBC with a pronounced shift to the left. In all cases, X-ray examinations demonstrated extended, mainly unilateral and often remarkedly peripheral infiltrations of the lung. On the basis of the clinical course, two groups could be distinguished: (a) non-complicated cases of @entity2 with rapid improvement within 2-3 weeks; and (b) cases with a protracted sometimes severe course with persistence of the infiltrations up to 4 months and more. All @entity0 with a protracted course suffered from concomitant symptoms. Whereas none of the @entity0 died of @entity6 , two @entity0 died six months later from their underlying disease. Most @entity0 were treated with several antibiotics. In three @entity0 definite improvement occurred only after therapy had been changed to @entity8 . @entity7 , currently recommended as the drug of choice, was used in none of these cases.

title: [Clinical data on Legionnaires' disease. Report on 8 sporadic cases of XXXX ].

answer: @entity2


abstract: BACKGROUND: One hypothesis to explain the high rate of @entity3 and @entity1 ( @entity2 [ @entity1 ]) co-abuse is that these drugs have enhanced rewarding effects when taken together. The goal of this work was to use the conditioned place preference (CPP) procedure to determine whether @entity3 would enhance the development of @entity1 -induced CPP. METHODS: The conditioned rewarding effects of @entity3 (1 or 2  mg/kg of @entity3 tartrate), @entity1 (1  g/kg), and @entity3 plus @entity1 in combination were assessed using a well-established CPP procedure chosen specifically for examining alterations in the development of @entity1 -induced CPP by @entity3 . In addition, the reference dose procedure was used to directly compare the conditioned rewarding effect of @entity1 versus @entity3 plus @entity1 . DBA/2J @entity0 were used because they are an inbred strain that has repeatedly been shown to develop CPP to @entity1 . RESULTS: Neither dose of @entity3 alone produced CPP, whereas @entity1 did, using the standard @entity1 CPP procedure. The magnitude of @entity1 -induced CPP was not affected by co-administration of 1  mg/kg @entity3 , but 2  mg/kg @entity3 interfered with the development of @entity1 -induced CPP. Using the reference dose procedure, there was no significant preference or aversion for either @entity3  +  @entity1 dose combination versus @entity1 alone. However, combined @entity3 and @entity1 had a larger effect on locomotor activity, during the conditioning trials, compared to their additive effect when given alone, consistent with previous data. CONCLUSIONS: These data do not support the hypothesis that @entity3 enhances the conditioned rewarding effect of @entity1 . This finding differs from the combined locomotor stimulant effects of @entity3 and @entity1 that were observed in this study and in our previously published work, and suggests that combined stimulant effects of @entity3 and @entity1 do not predict enhanced reward.

title: XXXX enhances the locomotor stimulating but not the conditioned rewarding effect of @entity2 in DBA/2J @entity0 .

answer: @entity3


abstract: BACKGROUND: One hypothesis to explain the high rate of @entity3 and @entity1 ( @entity2 [ @entity1 ]) co-abuse is that these drugs have enhanced rewarding effects when taken together. The goal of this work was to use the conditioned place preference (CPP) procedure to determine whether @entity3 would enhance the development of @entity1 -induced CPP. METHODS: The conditioned rewarding effects of @entity3 (1 or 2  mg/kg of @entity3 tartrate), @entity1 (1  g/kg), and @entity3 plus @entity1 in combination were assessed using a well-established CPP procedure chosen specifically for examining alterations in the development of @entity1 -induced CPP by @entity3 . In addition, the reference dose procedure was used to directly compare the conditioned rewarding effect of @entity1 versus @entity3 plus @entity1 . DBA/2J @entity0 were used because they are an inbred strain that has repeatedly been shown to develop CPP to @entity1 . RESULTS: Neither dose of @entity3 alone produced CPP, whereas @entity1 did, using the standard @entity1 CPP procedure. The magnitude of @entity1 -induced CPP was not affected by co-administration of 1  mg/kg @entity3 , but 2  mg/kg @entity3 interfered with the development of @entity1 -induced CPP. Using the reference dose procedure, there was no significant preference or aversion for either @entity3  +  @entity1 dose combination versus @entity1 alone. However, combined @entity3 and @entity1 had a larger effect on locomotor activity, during the conditioning trials, compared to their additive effect when given alone, consistent with previous data. CONCLUSIONS: These data do not support the hypothesis that @entity3 enhances the conditioned rewarding effect of @entity1 . This finding differs from the combined locomotor stimulant effects of @entity3 and @entity1 that were observed in this study and in our previously published work, and suggests that combined stimulant effects of @entity3 and @entity1 do not predict enhanced reward.

title: @entity3 enhances the locomotor stimulating but not the conditioned rewarding effect of XXXX in DBA/2J @entity0 .

answer: @entity2


abstract: BACKGROUND: One hypothesis to explain the high rate of @entity3 and @entity1 ( @entity2 [ @entity1 ]) co-abuse is that these drugs have enhanced rewarding effects when taken together. The goal of this work was to use the conditioned place preference (CPP) procedure to determine whether @entity3 would enhance the development of @entity1 -induced CPP. METHODS: The conditioned rewarding effects of @entity3 (1 or 2  mg/kg of @entity3 tartrate), @entity1 (1  g/kg), and @entity3 plus @entity1 in combination were assessed using a well-established CPP procedure chosen specifically for examining alterations in the development of @entity1 -induced CPP by @entity3 . In addition, the reference dose procedure was used to directly compare the conditioned rewarding effect of @entity1 versus @entity3 plus @entity1 . DBA/2J @entity0 were used because they are an inbred strain that has repeatedly been shown to develop CPP to @entity1 . RESULTS: Neither dose of @entity3 alone produced CPP, whereas @entity1 did, using the standard @entity1 CPP procedure. The magnitude of @entity1 -induced CPP was not affected by co-administration of 1  mg/kg @entity3 , but 2  mg/kg @entity3 interfered with the development of @entity1 -induced CPP. Using the reference dose procedure, there was no significant preference or aversion for either @entity3  +  @entity1 dose combination versus @entity1 alone. However, combined @entity3 and @entity1 had a larger effect on locomotor activity, during the conditioning trials, compared to their additive effect when given alone, consistent with previous data. CONCLUSIONS: These data do not support the hypothesis that @entity3 enhances the conditioned rewarding effect of @entity1 . This finding differs from the combined locomotor stimulant effects of @entity3 and @entity1 that were observed in this study and in our previously published work, and suggests that combined stimulant effects of @entity3 and @entity1 do not predict enhanced reward.

title: @entity3 enhances the locomotor stimulating but not the conditioned rewarding effect of @entity2 in DBA/2J XXXX .

answer: @entity0


abstract: OBJECTIVE: To assess the estimated 10-year risk of @entity2 among @entity4 outpatients known with @entity1 from cardiovascular clinics of 36 tertiary hospitals in China and to analyze the characteristics of the risk factors and the 10-year risk of @entity2 between the southern and the northern @entity0 . METHODS: A multi-center prevalence survey was conducted from October 2011 to June 2012. @entity4 outpatients known with @entity1 were enrolled from cardiovascular clinics of 36 tertiary hospitals in China. A total of 15 914 outpatients were included in the final analysis. The 10-year probability of @entity2 was evaluated by the Framingham @entity2 risk profile. According to the 10-year probability of @entity2 , @entity0 were divided into low risk (  <= 5%), medium risk (6%   9%) and high risk ( >=  10%). RESULTS: (1) Of all the @entity4 outpatients known with @entity1 , the mean age was (64.6    10.1) years and the mean systolic pressure was (138.7    19.3) mmHg (1 mmHg = 0.133 kPa). Among them, 7.4% with @entity5 , 11.2% with @entity6 , 57.2% with @entity3 , 17.1% smokers and 37.0% using mono-hypoglycemic agent. The southern @entity0 who were older with more smokers had higher proportions of @entity0 and @entity6 , lower levels of systolic blood pressure, and lower proportions of other @entity3 than those of the northern @entity0 ( all P < 0.05). (2) The mean 10-year probability of @entity2 was (20.9    16.2) %. The southern @entity0 had a higher mean 10-year probability of @entity2 than that of the northern @entity0 [(22.4    17.1) % vs (19.7    15.2) %] (P < 0.01) . After adjusted by age and sex, the southern @entity0 still had a higher mean 10-year probability of @entity2 (P < 0.05) . (3) All the @entity0 had 7.7% with low risk, 17.4% with medium risk, and 74.9% with high risk. The southern @entity0 had lower proportions of low and medium risk than those of the northern @entity0 (6.7% vs 8.4%, 15.5% vs 18.9%), but had a higher proportion of high risk than that of the northern @entity0 (77.7% vs 72.7%, all P < 0.01). CONCLUSIONS: Among the @entity4 outpatients known with @entity1 from the cardiovascular clinics of our study, most of them were at the 10-year high risk of @entity2 . The southern @entity0 had a higher mean 10-year probability of @entity2 than that of the northern @entity0 .

title: [The 10-year XXXX risk in @entity4 outpatients combined with @entity1 in cardiovascular clinics of 36 tertiary hospitals in China].

answer: @entity2


abstract: OBJECTIVE: To assess the estimated 10-year risk of @entity2 among @entity4 outpatients known with @entity1 from cardiovascular clinics of 36 tertiary hospitals in China and to analyze the characteristics of the risk factors and the 10-year risk of @entity2 between the southern and the northern @entity0 . METHODS: A multi-center prevalence survey was conducted from October 2011 to June 2012. @entity4 outpatients known with @entity1 were enrolled from cardiovascular clinics of 36 tertiary hospitals in China. A total of 15 914 outpatients were included in the final analysis. The 10-year probability of @entity2 was evaluated by the Framingham @entity2 risk profile. According to the 10-year probability of @entity2 , @entity0 were divided into low risk (  <= 5%), medium risk (6%   9%) and high risk ( >=  10%). RESULTS: (1) Of all the @entity4 outpatients known with @entity1 , the mean age was (64.6    10.1) years and the mean systolic pressure was (138.7    19.3) mmHg (1 mmHg = 0.133 kPa). Among them, 7.4% with @entity5 , 11.2% with @entity6 , 57.2% with @entity3 , 17.1% smokers and 37.0% using mono-hypoglycemic agent. The southern @entity0 who were older with more smokers had higher proportions of @entity0 and @entity6 , lower levels of systolic blood pressure, and lower proportions of other @entity3 than those of the northern @entity0 ( all P < 0.05). (2) The mean 10-year probability of @entity2 was (20.9    16.2) %. The southern @entity0 had a higher mean 10-year probability of @entity2 than that of the northern @entity0 [(22.4    17.1) % vs (19.7    15.2) %] (P < 0.01) . After adjusted by age and sex, the southern @entity0 still had a higher mean 10-year probability of @entity2 (P < 0.05) . (3) All the @entity0 had 7.7% with low risk, 17.4% with medium risk, and 74.9% with high risk. The southern @entity0 had lower proportions of low and medium risk than those of the northern @entity0 (6.7% vs 8.4%, 15.5% vs 18.9%), but had a higher proportion of high risk than that of the northern @entity0 (77.7% vs 72.7%, all P < 0.01). CONCLUSIONS: Among the @entity4 outpatients known with @entity1 from the cardiovascular clinics of our study, most of them were at the 10-year high risk of @entity2 . The southern @entity0 had a higher mean 10-year probability of @entity2 than that of the northern @entity0 .

title: [The 10-year @entity2 risk in XXXX outpatients combined with @entity1 in cardiovascular clinics of 36 tertiary hospitals in China].

answer: @entity4


abstract: OBJECTIVE: To assess the estimated 10-year risk of @entity2 among @entity4 outpatients known with @entity1 from cardiovascular clinics of 36 tertiary hospitals in China and to analyze the characteristics of the risk factors and the 10-year risk of @entity2 between the southern and the northern @entity0 . METHODS: A multi-center prevalence survey was conducted from October 2011 to June 2012. @entity4 outpatients known with @entity1 were enrolled from cardiovascular clinics of 36 tertiary hospitals in China. A total of 15 914 outpatients were included in the final analysis. The 10-year probability of @entity2 was evaluated by the Framingham @entity2 risk profile. According to the 10-year probability of @entity2 , @entity0 were divided into low risk (  <= 5%), medium risk (6%   9%) and high risk ( >=  10%). RESULTS: (1) Of all the @entity4 outpatients known with @entity1 , the mean age was (64.6    10.1) years and the mean systolic pressure was (138.7    19.3) mmHg (1 mmHg = 0.133 kPa). Among them, 7.4% with @entity5 , 11.2% with @entity6 , 57.2% with @entity3 , 17.1% smokers and 37.0% using mono-hypoglycemic agent. The southern @entity0 who were older with more smokers had higher proportions of @entity0 and @entity6 , lower levels of systolic blood pressure, and lower proportions of other @entity3 than those of the northern @entity0 ( all P < 0.05). (2) The mean 10-year probability of @entity2 was (20.9    16.2) %. The southern @entity0 had a higher mean 10-year probability of @entity2 than that of the northern @entity0 [(22.4    17.1) % vs (19.7    15.2) %] (P < 0.01) . After adjusted by age and sex, the southern @entity0 still had a higher mean 10-year probability of @entity2 (P < 0.05) . (3) All the @entity0 had 7.7% with low risk, 17.4% with medium risk, and 74.9% with high risk. The southern @entity0 had lower proportions of low and medium risk than those of the northern @entity0 (6.7% vs 8.4%, 15.5% vs 18.9%), but had a higher proportion of high risk than that of the northern @entity0 (77.7% vs 72.7%, all P < 0.01). CONCLUSIONS: Among the @entity4 outpatients known with @entity1 from the cardiovascular clinics of our study, most of them were at the 10-year high risk of @entity2 . The southern @entity0 had a higher mean 10-year probability of @entity2 than that of the northern @entity0 .

title: [The 10-year @entity2 risk in @entity4 outpatients combined with XXXX in cardiovascular clinics of 36 tertiary hospitals in China].

answer: @entity1


abstract: Experimental @entity2 was induced by implanting gallstones from @entity0 beings into the gallbladder of the cat. Three months later the concentrating function of the gallbladder, the motility, and hepatic bile flow were studied by a perfusion technique in the anesthetized animal. Gallbladder function was correlated to morphologic changes. After 3 months, the cystic duct was patent in nine animals and bile was found in the gallbladder. In 17 animals the cystic duct was obstructed and colorless contents were found in the gallbladder. Animals with a patent cystic duct showed slight or moderate @entity1 and intact concentrating activity in the gallbladder, whereas animals with obstructed animals had pronounced @entity1 and continuous fluid "secretion" into the lumen. Both groups had increased bile outflow from the liver. @entity4 , a prostaglandin synthetase inhibitor, promptly reversed gallbladder fluid "secretion" into absorption and reduced the increased bile flow to a normal level. These results are discussed in relation to clinical findings in @entity0 . A mechanism by which @entity3 are responsible for the inflammatory gallbladder "secretion" and the increased bile flow from the liver is proposed.

title: Gallbladder function in experimental XXXX .

answer: @entity2


abstract: OBJECTIVE: This study aimed to evaluate the value of different follow-up methods for the detection of first recurrence in @entity2 @entity0 in first complete remission (CR), and to find reasonable long-term follow-up strategies. METHODS: We retrospectively analyzed 277 @entity2 @entity0 who achieved CR after first-line therapies and subsequently relapsed. All @entity0 were divided into routine surveillance imaging group (group A) and irregular imaging follow-up visit group (group B). To compare the two groups of @entity0 with @entity1 burden ( @entity1 diameter and number of @entity1 invasion areas) at the time of relapse, and the number of imaging scans before the relapse. To analyze the main ways of finding @entity2 in the two groups. RESULTS: Among a total of 277 @entity0 , there were 187 @entity0 in the group A and 90 @entity0 in the group B. The @entity1 recurrence occurred in 120 cases (43.3%) within the first year, and 76 @entity0 (27.4%) in the second year. At the time of diagnosis of recurrence, the average maximum diameter of @entity1 in the groups A and B were (3.2    2.2) cm and (3.8    2.9) cm, respectively (P = 0.123). The two groups showed slight difference in number of @entity1 invasion areas (P = 0.050). At the time of diagnosis of recurrence, there were 3 of 121 @entity0 (2.5%) with maximum diameter of @entity1 more than 8 cm in the group A and 6 of 49 cases (12.2%) in the group B (P = 0.018). In the group A, the @entity0 had in average 4.9 times of imaging scans before recurrence, significantly more than the 0.22 times in the group B (P < 0.001). Among all @entity0 , the diagnosis of recurrence was based on imaging scans only in 59 @entity0 (21.3%). CONCLUSIONS: @entity2 @entity0 do not benefit from routine surveillance imaging to detect the @entity1 recurrence. It indicates that we should not rely solely on imaging examinations at follow-up visits, and should pay more attention on clinical signs and symptoms.

title: [Efficacy analysis of different follow-up methods in detecting first recurrence of XXXX ].

answer: @entity2


abstract: Rapid endothelialization is important for biodegradable blood-contacting devices not only to prevent @entity1 but also to prevent degradation debris from entering the bloodstream and causing further complications. Here the authors report a three-step surface modification method, by which biomolecules, such as gelatin and chitosan, are covalently immobilized on the surface of plasma-treated @entity4 ( @entity5 ) via - @entity2 groups introduced by @entity3 grafting polymerization. Surface characterization techniques, including x-ray photoelectron spectroscopy, contact angle measurement, and colorimetric methods for surface density of functional groups, proved the feasibility and stability of this surface modification method. Surface wettability was increased by biomolecules immobilization. The - @entity2 surface density was measured to be 4.17  0.15    mol/cm(2), the and amount of gelatin immobilized was 4.8    g/cm(2). @entity0 umbilical vein endothelial cell was used during in vitro study at seeding density of 10(4)   cells/cm(2). @entity5 -gAA-gelatin surface was found to enhance cell adhesion, spreading, focal adhesion formation, and proliferation significantly. Chitosan-modified @entity5 shows marginally improvement in cell adhesion and proliferation. Endothelialization was achieved within 7 days on both modified @entity5 surfaces. In conclusion, this work demonstrates the feasibility of the surface modification method, and its ability to promote complete endothelialization for cardiovascular applications.

title: Surface modification of XXXX with biomolecules to promote endothelialization.

answer: @entity4


abstract: BACKGROUND _ AIMS: Unhealthy lifestyles predispose to @entity8 ( @entity8 ), which may further result in the development of @entity3 ( @entity3 ). Although @entity8 @entity0 benefit from physical activity, it is unknown whether regular exercise reduces the risk of developing @entity3 . Therefore, we studied the effect of regular exercise on the development of @entity3 in male hepatocyte-specific @entity6 -deficient @entity2 (AlbCrePten(flox/flox)), which develop @entity4 and @entity3 spontaneously. METHODS: @entity2 were fed a standardized 10% fat diet and were randomly divided into exercise or sedentary groups. The exercise group ran on a motorized treadmill for 60 minutes/day, 5 days/week during 32 weeks. RESULTS: After 32 weeks of regular exercise, 71% of exercised @entity2 developed nodules larger than 15 mm(3) vs 100% of @entity2 in the sedentary group. The mean number of @entity1 per liver was reduced by exercise, as well as the total tumoral volume per liver. Exercise did not affect @entity4 and had no effect on the @entity5 ( @entity5 ) Activity Score (NAS). Exercise decreased @entity1 cell proliferation. Mechanistically, exercise stimulated the phosphorylation of AMPK and its substrate raptor, which decreased the kinase activity of @entity7 . CONCLUSIONS: These data show a benefit of regular exercise on the development of @entity3 in an experimental model of @entity8 and offer a rationale for encouraging predisposed @entity0 to increase their physical activity for the prevention of @entity3 .

title: Regular exercise decreases liver tumors development in hepatocyte-specific XXXX -deficient @entity2 independently of @entity4 .

answer: @entity6


abstract: BACKGROUND _ AIMS: Unhealthy lifestyles predispose to @entity8 ( @entity8 ), which may further result in the development of @entity3 ( @entity3 ). Although @entity8 @entity0 benefit from physical activity, it is unknown whether regular exercise reduces the risk of developing @entity3 . Therefore, we studied the effect of regular exercise on the development of @entity3 in male hepatocyte-specific @entity6 -deficient @entity2 (AlbCrePten(flox/flox)), which develop @entity4 and @entity3 spontaneously. METHODS: @entity2 were fed a standardized 10% fat diet and were randomly divided into exercise or sedentary groups. The exercise group ran on a motorized treadmill for 60 minutes/day, 5 days/week during 32 weeks. RESULTS: After 32 weeks of regular exercise, 71% of exercised @entity2 developed nodules larger than 15 mm(3) vs 100% of @entity2 in the sedentary group. The mean number of @entity1 per liver was reduced by exercise, as well as the total tumoral volume per liver. Exercise did not affect @entity4 and had no effect on the @entity5 ( @entity5 ) Activity Score (NAS). Exercise decreased @entity1 cell proliferation. Mechanistically, exercise stimulated the phosphorylation of AMPK and its substrate raptor, which decreased the kinase activity of @entity7 . CONCLUSIONS: These data show a benefit of regular exercise on the development of @entity3 in an experimental model of @entity8 and offer a rationale for encouraging predisposed @entity0 to increase their physical activity for the prevention of @entity3 .

title: Regular exercise decreases liver tumors development in hepatocyte-specific @entity6 -deficient @entity2 independently of XXXX .

answer: @entity4


abstract: BACKGROUND _ AIMS: Unhealthy lifestyles predispose to @entity8 ( @entity8 ), which may further result in the development of @entity3 ( @entity3 ). Although @entity8 @entity0 benefit from physical activity, it is unknown whether regular exercise reduces the risk of developing @entity3 . Therefore, we studied the effect of regular exercise on the development of @entity3 in male hepatocyte-specific @entity6 -deficient @entity2 (AlbCrePten(flox/flox)), which develop @entity4 and @entity3 spontaneously. METHODS: @entity2 were fed a standardized 10% fat diet and were randomly divided into exercise or sedentary groups. The exercise group ran on a motorized treadmill for 60 minutes/day, 5 days/week during 32 weeks. RESULTS: After 32 weeks of regular exercise, 71% of exercised @entity2 developed nodules larger than 15 mm(3) vs 100% of @entity2 in the sedentary group. The mean number of @entity1 per liver was reduced by exercise, as well as the total tumoral volume per liver. Exercise did not affect @entity4 and had no effect on the @entity5 ( @entity5 ) Activity Score (NAS). Exercise decreased @entity1 cell proliferation. Mechanistically, exercise stimulated the phosphorylation of AMPK and its substrate raptor, which decreased the kinase activity of @entity7 . CONCLUSIONS: These data show a benefit of regular exercise on the development of @entity3 in an experimental model of @entity8 and offer a rationale for encouraging predisposed @entity0 to increase their physical activity for the prevention of @entity3 .

title: Regular exercise decreases liver tumors development in hepatocyte-specific @entity6 -deficient XXXX independently of @entity4 .

answer: @entity2


abstract: The relationship between central conduction time (CCT) and levels of regional blood flow were studied in 9 primates. Flows were recorded in both hemispheres using the method of @entity3 (2 min) clearance. The somatosensory evoked potentials were recorded over the contralateral cortex and the dorsal columns, following median nerve stimulation. The CCT, a measure of the brain's electrical conduction, was determined by the difference in latencies between N10, (the arrival of the afferent volley at the sensory cortex) and N7 (its arrival at the dorsal column). @entity0 was produced by transorbital occlusion of the right middle cerebral artery. In the acute @entity0 phase within 5 minute of occlusion, there was a significant correlation between the change in CCT and the decrease in flow. In the later occlusive phase, the CCT was unaltered with flows above 15 ml/100g/min. Below that level smaller decreases in flow resulted in progressively larger changes in CCT until a flow was reached where the N10 disappeared or the entire cortex was electrically silent. Focal @entity0 had no effect on the first positive deflection recorded from the cortex (P8) or the first negative peak response from the cervical region (N7). However, the latency of P8 was increased or it was absent with the introduction of @entity1 , while N8 was unaltered. From our measurements, it appears that prolongation of CCT can be related to developing @entity0 , and that the thresholds for change are not dissimilar to those already recorded for somatosensory evoked responses to the basis of amplitude alterations in the cortex. Below these levels, prolongation of CCT appears to bear a parametric relationship to alteration in blood flow. While the measurement displays only one of the many alterations which are induced by @entity0 in the brain, its attraction lies in its simplicity and in the fact that it may be applied with relative ease in the clinical situation. Under these circumstances, it appears to be an adequately sensitive monitor of developing @entity2 , and deserves further study.

title: Central conduction time in primate XXXX -- a study in baboons.

answer: @entity2


abstract: OBJECTIVE: Mutations in the @entity3 gene are responsible for hereditary @entity2 ( @entity2 ) and may vary between ethnic groups. We report the spectrum of mutations detected in @entity0 with @entity2 in a referral center in Greece. @entity0 AND METHODS: Screening for @entity3 mutations was performed in 313 subjects from 188 unrelated families: 51 @entity0 had clinical suspicion for @entity1 , 133 were apparently sporadic, four @entity0 had only C cell hyperplasia, and 125 were family members. Exons 8, 10, 11, and 13-16 were screened. RESULTS: A total of 58 individuals (30.85%) were @entity3 mutations carriers, 120 (63.8%) were finally classified as sporadic, 13 apparently sporadic cases (9.8%) were identified with @entity3 mutation: ten carried the exon 8 at codon 533 mutation (previously reported), two the exon 14 at codon 804 mutation, and one the exon 13 at codon 768 mutation. Six @entity0 (3.19%) with clinical features of @entity4 and negative for @entity3 mutations were classified as 'unknown cause'. The mutations of hereditary cases were as follows: 21 cases (36.2%) in exon 8 codon 533, 19 (32.8%) in exon 11 codon 634, nine (15.5%) in exon 10, five (8.6%) in exon 16, three (5.2%) in exon 14 codon 804, and one in exon 13 codon 768 (1.7%). CONCLUSION: The spectrum of @entity3 mutations in Greece differs from that in other populations and the prevalence of familial cases is higher. The exon 8 ( @entity5 ) mutation was the most prevalent in familial cases unlike other series, followed by exon 11 (codon 634) mutations which are the most frequent elsewhere. The wide application of genetic screening in @entity2 reveals new molecular defects and helps to characterize the spectrum of mutations in each ethnic group.

title: Genetic screening of @entity0 with XXXX in a referral center in Greece during the past two decades.

answer: @entity2


abstract: OBJECTIVE: Mutations in the @entity3 gene are responsible for hereditary @entity2 ( @entity2 ) and may vary between ethnic groups. We report the spectrum of mutations detected in @entity0 with @entity2 in a referral center in Greece. @entity0 AND METHODS: Screening for @entity3 mutations was performed in 313 subjects from 188 unrelated families: 51 @entity0 had clinical suspicion for @entity1 , 133 were apparently sporadic, four @entity0 had only C cell hyperplasia, and 125 were family members. Exons 8, 10, 11, and 13-16 were screened. RESULTS: A total of 58 individuals (30.85%) were @entity3 mutations carriers, 120 (63.8%) were finally classified as sporadic, 13 apparently sporadic cases (9.8%) were identified with @entity3 mutation: ten carried the exon 8 at codon 533 mutation (previously reported), two the exon 14 at codon 804 mutation, and one the exon 13 at codon 768 mutation. Six @entity0 (3.19%) with clinical features of @entity4 and negative for @entity3 mutations were classified as 'unknown cause'. The mutations of hereditary cases were as follows: 21 cases (36.2%) in exon 8 codon 533, 19 (32.8%) in exon 11 codon 634, nine (15.5%) in exon 10, five (8.6%) in exon 16, three (5.2%) in exon 14 codon 804, and one in exon 13 codon 768 (1.7%). CONCLUSION: The spectrum of @entity3 mutations in Greece differs from that in other populations and the prevalence of familial cases is higher. The exon 8 ( @entity5 ) mutation was the most prevalent in familial cases unlike other series, followed by exon 11 (codon 634) mutations which are the most frequent elsewhere. The wide application of genetic screening in @entity2 reveals new molecular defects and helps to characterize the spectrum of mutations in each ethnic group.

title: Genetic screening of XXXX with @entity2 in a referral center in Greece during the past two decades.

answer: @entity0


abstract: This study aimed at identifying the dose metric applicable to studies on the viability of cells exposed to nanoparticles (NPs) in vitro. A previously reported set of data was evaluated very carefully. The extent of cell death after 24-h exposure of three cell lines to suspended @entity3 NPs (<30 nm) was quantified using four different viability/ @entity1 assays. Data on NP uptake in cells after 6-h exposure were also reported. Evidence is provided that, in spite of the small size of the NPs, mass transport to the cells cannot be explained solely by diffusion. Gravitational settling must have contributed significantly, presumably as the result of the formation of large agglomerates. Appropriately adjusted response data, with typically 22 combinations of mass concentration and height of the medium for each cell line, could be integrated in universal diagrams, provided the dose was quoted in terms of the areal density of NP mass delivered to the cells. @entity2 became observable only if cells were exposed to the equivalent of 1 to 5 closely packed layers of NPs; the dose required for complete cell death ranged between 4 and about 20 layers of NPs. The results suggest that the cell-death phenomena observed in the evaluated work and in many similar studies reported in the literature constitute a matter of cell overload with @entity0 . This finding also implies that the toxic potential of individual @entity4 NPs is very low. Strategies for the design of advanced future work are outlined.

title: Novel dose metric for apparent XXXX effects generated by in vitro cell exposure to @entity3 nanoparticles.

answer: @entity1


abstract: This study aimed at identifying the dose metric applicable to studies on the viability of cells exposed to nanoparticles (NPs) in vitro. A previously reported set of data was evaluated very carefully. The extent of cell death after 24-h exposure of three cell lines to suspended @entity3 NPs (<30 nm) was quantified using four different viability/ @entity1 assays. Data on NP uptake in cells after 6-h exposure were also reported. Evidence is provided that, in spite of the small size of the NPs, mass transport to the cells cannot be explained solely by diffusion. Gravitational settling must have contributed significantly, presumably as the result of the formation of large agglomerates. Appropriately adjusted response data, with typically 22 combinations of mass concentration and height of the medium for each cell line, could be integrated in universal diagrams, provided the dose was quoted in terms of the areal density of NP mass delivered to the cells. @entity2 became observable only if cells were exposed to the equivalent of 1 to 5 closely packed layers of NPs; the dose required for complete cell death ranged between 4 and about 20 layers of NPs. The results suggest that the cell-death phenomena observed in the evaluated work and in many similar studies reported in the literature constitute a matter of cell overload with @entity0 . This finding also implies that the toxic potential of individual @entity4 NPs is very low. Strategies for the design of advanced future work are outlined.

title: Novel dose metric for apparent @entity1 effects generated by in vitro cell exposure to XXXX nanoparticles.

answer: @entity3


abstract: BACKGROUND: Self-rated health (SRH) is an important predictor of objective health-related outcomes that, according to the Cognitive Process Model of SRH, is influenced by contextual factors (symptoms and @entity5 ). Although research indicates that @entity5 contours SRH, less attention has been given to understanding the contributions of @entity5 to future self-rated health (FSRH) or the contextual factors that play a role in shaping these effects. PURPOSE: The aim of the present study was to extend the theory and research on FSRH by exploring the contributions of @entity5 , current SRH, and @entity4 to FSRH in the context of @entity1 , and to test the potential mediating role of optimism for explaining these effects. METHOD: Two @entity1 samples ( @entity2 , N   =   365, and @entity0 , @entity6 ; N   =   290) completed identical surveys. A hierarchical regression model with age, education, and current health, and @entity4 entered in the first two steps and traits entered in the last step, tested the effects of @entity5 on FSRH. Mediation analyses controlling for contextual variables tested the explanatory role of optimism. RESULTS: Fatigue was a significant contributor to FSRH accounting for 11  % of the variance in the @entity2 sample and 17  % in the @entity6 sample over the demographic variables. Both Agreeableness and @entity3 accounted for additional significant but modest variance in FSRH (4  %); Agreeableness was associated with higher FSRH, whereas @entity3 was associated with lower FSRH. For both traits, optimism fully explained the associations with FSRH. CONCLUSION: After accounting for the influence of @entity4 and other variables, the contributions of high Agreeableness and low @entity3 to FSRH are modest in the context of @entity1 , and these associations may be explained by optimism.

title: Who Looks Forward to Better Health? Personality Factors and Future Self-Rated Health in the Context of XXXX .

answer: @entity1


abstract: BACKGROUND: SAHA ( @entity6 , @entity5 , Hirsutism and Androgenetic Alopecia) syndrome is a @entity1 , with variant response to treatment. Triad of cutaneous @entity4 included nodulocystic or severe acne, female pattern hair loss and @entity3 . AIM: The aim of this study is to compare the effectiveness of isotretinoin and cyproterone compound in the treatment of @entity5 , in @entity0 with @entity2 or triad of cutaneous @entity4 . MATERIALS AND METHODS: 30 female @entity0 with @entity2 were divided randomly into two groups. Group A was treated with cyproterone compound from day 5 of menstrual cycle onwards for 3 weeks and a week without it and group B received isotretinoin, with a dose of 0.75 mg/kg per day from the beginning of menses onwards for 4 months. The results were evaluated by a blind dermatologist using @entity5 Severity Index (ASI) score at baseline and monthly for 4 months. RESULTS: Despite a continuous reduction in ASI score in both the groups, according to both physician (P = 0.63) and @entity0 (P = 0.25) assessment, cyproterone compound was not statistically more effective than conventional treatment of @entity5 at the end of the study. Side-effects were reported in @entity0 in both groups, generally being mild and tolerable except in two subjects. CONCLUSION: This study indicates that cyproterone compound is not superior to isotretinoin in the treatment of @entity5 in @entity0 with @entity2 or triad of cutaneous @entity4 . Indeed, other studies are needed to evaluate the effect of cyproterone compound (regardless of androgen level) and isotretinoin in subjects with only @entity5 .

title: The efficacy of oral isotretinoin versus cyproterone compound in female @entity0 with acne and the triad of cutaneous XXXX : A randomized clinical trial.

answer: @entity4


abstract: BACKGROUND: SAHA ( @entity6 , @entity5 , Hirsutism and Androgenetic Alopecia) syndrome is a @entity1 , with variant response to treatment. Triad of cutaneous @entity4 included nodulocystic or severe acne, female pattern hair loss and @entity3 . AIM: The aim of this study is to compare the effectiveness of isotretinoin and cyproterone compound in the treatment of @entity5 , in @entity0 with @entity2 or triad of cutaneous @entity4 . MATERIALS AND METHODS: 30 female @entity0 with @entity2 were divided randomly into two groups. Group A was treated with cyproterone compound from day 5 of menstrual cycle onwards for 3 weeks and a week without it and group B received isotretinoin, with a dose of 0.75 mg/kg per day from the beginning of menses onwards for 4 months. The results were evaluated by a blind dermatologist using @entity5 Severity Index (ASI) score at baseline and monthly for 4 months. RESULTS: Despite a continuous reduction in ASI score in both the groups, according to both physician (P = 0.63) and @entity0 (P = 0.25) assessment, cyproterone compound was not statistically more effective than conventional treatment of @entity5 at the end of the study. Side-effects were reported in @entity0 in both groups, generally being mild and tolerable except in two subjects. CONCLUSION: This study indicates that cyproterone compound is not superior to isotretinoin in the treatment of @entity5 in @entity0 with @entity2 or triad of cutaneous @entity4 . Indeed, other studies are needed to evaluate the effect of cyproterone compound (regardless of androgen level) and isotretinoin in subjects with only @entity5 .

title: The efficacy of oral isotretinoin versus cyproterone compound in female XXXX with acne and the triad of cutaneous @entity4 : A randomized clinical trial.

answer: @entity0